Neuroanesthesia & neurocritical care
Using metabolomics to predict severe traumatic brain injury outcome (Glasgow outcome scale extended (GOSE)) at 3 and 12 months
Authors' conclusion
Metabolomic profiles were strongly associated with the prognosis of GOSE outcome at 3 and 12 months and mortality following sTBI in adults.
Study context
- Population
- Adults with severe TBI (GCS ≤ 8), multicentre Canadian TBI (CanTBI) study
- Participants
- 59 adults
- Exposure
- Favorable vs Unfavorable
- Outcome
- GOSE outcome, dichotomized into favorable (GOSE 5-8) and unfavorable (GOSE 1-4)
- Follow-up
- 3 and 12 months post-injury
Methodological detailsmulticentre, prognostic, metabolomic profiling
- Multicentre
- Prognostic
- Metabolomic profiling
Main finding
As reported in the abstract
Prediction of GOSE outcome at 3 and 12 months and mortality at 3 months by serum metabolic profiles (days 1 and 4)
Predictive ability (Q2), days 1 and 4
Q2 > 0.4-0.5
Accuracy (AUC), days 1 and 4
AUC > 0.99
Day 4 profiles more predictive than day 1
Q2 > 0.55
Observational data: associations, not effects.
Further findings
Metabolite changes day 1 to day 4
- Unfavorable outcomes associated with considerable metabolite changes from day 1 to day 4 vs favorable outcomes
Metabolites associated with poor outcome and mortality
- Increased lysophosphatidylcholines, acylcarnitines, energy-related metabolites (glucose, lactate), aromatic amino acids and glutamate associated with poor outcomes and mortality
Original publication
Using metabolomics to predict severe traumatic brain injury outcome (GOSE) at 3 and 12 months. Crit Care. Published 22 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →